Tags

Type your tag names separated by a space and hit enter

A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections.

Abstract

Vitamin D has been shown to be an important immune system regulator. Vitamin D insufficiency during winter may cause increased susceptibility to upper respiratory tract infections (URIs). To determine whether vitamin D supplementation during the winter season prevents or decreases URI symptoms, 162 adults were randomized to receive 50 microg vitamin D3 (2000 IU) daily or matching placebo for 12 weeks. A bi-weekly questionnaire was used to record the incidence and severity of URI symptoms. There was no difference in the incidence of URIs between the vitamin D and placebo groups (48 URIs vs. 50 URIs, respectively, P=0.57). There was no difference in the duration or severity of URI symptoms between the vitamin D and placebo groups [5.4+/-4.8 days vs. 5.3+/-3.1 days, respectively, P=0.86 (95% CI for the difference in duration -1.8 to 2.1)]. The mean 25-hydroxyvitamin D level at baseline was similar in both groups (64.3+/-25.4 nmol/l in the vitamin D group; 63.0+/-25.8 nmol/l in the placebo group; n.s.). After 12 weeks, 25-hydroxyvitamin D levels increased significantly to 88.5+/-23.2 nmol/l in the vitamin D group, whereas there was no change in vitamin D levels in the placebo group. There was no benefit of vitamin D3 supplementation in decreasing the incidence or severity of symptomatic URIs during winter. Further studies are needed to determine the role of vitamin D in infection.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Bone Mineral Research Center, Winthrop University Hospital, Mineola, NY, USA.

    , , , , ,

    Source

    Epidemiology and infection 137:10 2009 Oct pg 1396-404

    MeSH

    Adolescent
    Adult
    Aged
    Aged, 80 and over
    Cholecalciferol
    Female
    Humans
    Male
    Middle Aged
    Placebos
    Respiratory Tract Infections
    Surveys and Questionnaires
    Young Adult

    Pub Type(s)

    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    19296870

    Citation

    Li-Ng, M, et al. "A Randomized Controlled Trial of Vitamin D3 Supplementation for the Prevention of Symptomatic Upper Respiratory Tract Infections." Epidemiology and Infection, vol. 137, no. 10, 2009, pp. 1396-404.
    Li-Ng M, Aloia JF, Pollack S, et al. A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections. Epidemiol Infect. 2009;137(10):1396-404.
    Li-Ng, M., Aloia, J. F., Pollack, S., Cunha, B. A., Mikhail, M., Yeh, J., & Berbari, N. (2009). A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections. Epidemiology and Infection, 137(10), pp. 1396-404. doi:10.1017/S0950268809002404.
    Li-Ng M, et al. A Randomized Controlled Trial of Vitamin D3 Supplementation for the Prevention of Symptomatic Upper Respiratory Tract Infections. Epidemiol Infect. 2009;137(10):1396-404. PubMed PMID: 19296870.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections. AU - Li-Ng,M, AU - Aloia,J F, AU - Pollack,S, AU - Cunha,B A, AU - Mikhail,M, AU - Yeh,J, AU - Berbari,N, Y1 - 2009/03/19/ PY - 2009/3/20/entrez PY - 2009/3/20/pubmed PY - 2009/9/22/medline SP - 1396 EP - 404 JF - Epidemiology and infection JO - Epidemiol. Infect. VL - 137 IS - 10 N2 - Vitamin D has been shown to be an important immune system regulator. Vitamin D insufficiency during winter may cause increased susceptibility to upper respiratory tract infections (URIs). To determine whether vitamin D supplementation during the winter season prevents or decreases URI symptoms, 162 adults were randomized to receive 50 microg vitamin D3 (2000 IU) daily or matching placebo for 12 weeks. A bi-weekly questionnaire was used to record the incidence and severity of URI symptoms. There was no difference in the incidence of URIs between the vitamin D and placebo groups (48 URIs vs. 50 URIs, respectively, P=0.57). There was no difference in the duration or severity of URI symptoms between the vitamin D and placebo groups [5.4+/-4.8 days vs. 5.3+/-3.1 days, respectively, P=0.86 (95% CI for the difference in duration -1.8 to 2.1)]. The mean 25-hydroxyvitamin D level at baseline was similar in both groups (64.3+/-25.4 nmol/l in the vitamin D group; 63.0+/-25.8 nmol/l in the placebo group; n.s.). After 12 weeks, 25-hydroxyvitamin D levels increased significantly to 88.5+/-23.2 nmol/l in the vitamin D group, whereas there was no change in vitamin D levels in the placebo group. There was no benefit of vitamin D3 supplementation in decreasing the incidence or severity of symptomatic URIs during winter. Further studies are needed to determine the role of vitamin D in infection. SN - 1469-4409 UR - https://www.unboundmedicine.com/medline/citation/19296870/A_randomized_controlled_trial_of_vitamin_D3_supplementation_for_the_prevention_of_symptomatic_upper_respiratory_tract_infections_ L2 - https://www.cambridge.org/core/product/identifier/S0950268809002404/type/journal_article DB - PRIME DP - Unbound Medicine ER -